Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Taylor

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Journal of Physics. Condensed Matter : an Institute of Physics Journal|March 10, 2011
Elastic relaxations associated with the Pm3m-R3c transition in LaAlO(3): III. Superattenuation of acoustic resonancesM A Carpenter, A Buckley, P A Taylor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2000
Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibodyP A Taylor, A Panoskaltsis-Mortari, R J Noelle, et al.
Blood|June 15, 1994
In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in miceB R Blazar, P A Taylor, P S Linsley, et al.
Cancer Research|September 15, 1993
Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2D A Vallera, P A Taylor, S L Aukerman, et al.
Virology|October 1, 1977
Molecular similarities among the adenovirus-associated virus polypeptides and evidence for a precursor proteinF B Johnson, T A Thomson, P A Taylor, et al.
British Medical Journal|March 11, 1972
Pulmonary complications after oesophagogastroscopy using diazepamP A Taylor, P B Cotton, R M Towey, et al.
Transplantation|September 15, 1996
Interleukin-1 alpha-mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host T cellsD A Vallera, P A Taylor, M B Widmer, et al.
Transplantation|December 27, 1994
The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inoculaB R Blazar, P A Taylor, G S Gray, et al.
The Journal of Clinical Investigation|August 6, 1998
CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responsesB R Blazar, P A Taylor, R J Noelle, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethalityB R Blazar, H J McKenna, A Panoskaltsis-Mortari, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Journal of Physics. Condensed Matter : an Institute of Physics Journal|March 10, 2011
Elastic relaxations associated with the Pm3m-R3c transition in LaAlO(3): III. Superattenuation of acoustic resonancesM A Carpenter, A Buckley, P A Taylor, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 7, 2000
Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibodyP A Taylor, A Panoskaltsis-Mortari, R J Noelle, et al.
Blood|June 15, 1994
In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in miceB R Blazar, P A Taylor, P S Linsley, et al.
Cancer Research|September 15, 1993
Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2D A Vallera, P A Taylor, S L Aukerman, et al.
Virology|October 1, 1977
Molecular similarities among the adenovirus-associated virus polypeptides and evidence for a precursor proteinF B Johnson, T A Thomson, P A Taylor, et al.
British Medical Journal|March 11, 1972
Pulmonary complications after oesophagogastroscopy using diazepamP A Taylor, P B Cotton, R M Towey, et al.
Transplantation|September 15, 1996
Interleukin-1 alpha-mediated promotion of long-term alloengraftment and short-term neutrophil expansion does not require the presence of either donor or host T cellsD A Vallera, P A Taylor, M B Widmer, et al.
Transplantation|December 27, 1994
The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inoculaB R Blazar, P A Taylor, G S Gray, et al.
The Journal of Clinical Investigation|August 6, 1998
CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responsesB R Blazar, P A Taylor, R J Noelle, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2001
Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethalityB R Blazar, H J McKenna, A Panoskaltsis-Mortari, et al.
Pageof 11